Therapy developer Alumis prices U.S. IPO at about $902 mln valuation (updated)

Alumis

28/06/2024 05:40

(Adds details from the report in paragraph 2, background in
3-5)
       June 27 (Reuters) - 
    Alumis  ALMS.O  set the pricing of its U.S. initial public
offering at $16 per share, the lower end of its price range,
valuing it at around $902 million.
  
        Previously known as Esker Therapeutics, Alumis is moving
ahead with its listing more than three months after it secured
an upsized $259 million Series C financing. It aims to raise
around $210 million, the company, involved in developing oral
therapies to address immune dysfunction said late on Thursday.
  
        Alumis expects to list on the Nasdaq under the symbol
"ALMS". Morgan Stanley, Leerink Partners, Cantor Fitzgerald and
Guggenheim Securities are the underwriters for the offering.
  

 (Reporting by Disha Mishra in Bengaluru; Editing by Mrigank
Dhaniwala and Nivedita Bhattacharjee)
 ((Disha.Mishra@thomsonreuters.com;))